530115-96-9

Basic information

• Product Name: 1-BOC-4-CYANO-4-METHYL-PIPERIDINE
• Synonyms: 1-BOC-4-CYANO-4-METHYL-PIPERIDINE;4-Cyano-4-methyl-piperidine-1-carboxylic acid tert-butyl ester;tert-butyl 4-cyano-4-Methylpiperidine-1-carboxylate;1-Boc-4-cyano-4-Methylpip...;Ert-Butyl 4-Cyano-4-Methylpiperidine-1-Carboxylate
• CAS NO: 530115-96-9
• Molecular Formula: C₁₂H₂₀N₂O₂
• Molecular Weight: 224.302
• Mol File: 530115-96-9.mol

Chemical Properties

• Boiling Point: 327.9±35.0 °C(Predicted)
• Appearance: /
• Density: 1.05±0.1 g/cm3 (20 ºC 760 Torr)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: -3.05±0.40(Predicted)
• CAS DataBase Reference: 1-BOC-4-CYANO-4-METHYL-PIPERIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-BOC-4-CYANO-4-METHYL-PIPERIDINE(530115-96-9)
• EPA Substance Registry System: 1-BOC-4-CYANO-4-METHYL-PIPERIDINE(530115-96-9)

Safety Data

• RIDADR: UN2811
• Hazardous Substances Data: 530115-96-9(Hazardous Substances Data)

Usage

Uses

1. Used in Pharmaceutical Industry:
1-BOC-4-CYANO-4-METHYL-PIPERIDINE is used as an intermediate compound for the synthesis of various pharmaceuticals. Its unique structure allows it to be a key component in the development of new drugs, particularly those targeting the central nervous system.
2. Used in Chemical Research:
1-BOC-4-CYANO-4-METHYL-PIPERIDINE is used as a research compound in the field of organic chemistry. Its properties and reactivity are studied to understand the behavior of piperidine derivatives and their potential applications in various chemical processes.
3. Used in Material Science:
1-BOC-4-CYANO-4-METHYL-PIPERIDINE is used as a building block in the synthesis of advanced materials, such as polymers and composites, with specific properties tailored for various applications, including electronics, coatings, and adhesives.
4. Used in Agrochemical Industry:
1-BOC-4-CYANO-4-METHYL-PIPERIDINE is used as a precursor in the synthesis of agrochemicals, such as pesticides and herbicides, to develop new and more effective products for agricultural use.
5. Used in Dye and Pigment Industry:
1-BOC-4-CYANO-4-METHYL-PIPERIDINE is used as a starting material in the production of dyes and pigments, contributing to the development of new colorants with improved properties, such as higher stability and better color intensity.

InChI:InChI=1S/C12H20N2O2/c1-11(2,3)16-10(15)14-7-5-12(4,9-13)6-8-14/h5-8H2,1-4H3

Upstream product

• 343788-67-0 4-carbamoyl-4-methylpiperidine-1-carboxylic acid tert-butyl ester 
• 407-25-0 trifluoroacetic anhydride 
• 91419-52-2 1-tert-butoxycarbonyl-4-cyanopiperidine 
• 74-88-4 methyl iodide 

Downstream Products

• 343788-67-0 4-carbamoyl-4-methylpiperidine-1-carboxylic acid tert-butyl ester 
• 948894-26-6 4-methylpiperidine-4-carbonitrile hydrochloride 
• 1257301-28-2 4-methylpiperidine-4-carboxamide hydrochloride 
• 948894-28-8 8-(benzyloxy)-5-{(1R)-1-{[tert-butyl(dimethyl)silyl]oxy}-2-[({4-methyl-1-[2-(2-phenylethoxy)ethyl]piperidin-4-yl}methyl)amino]ethyl}quinolin-2(1H)-one 
• 948894-30-2 8-(benzyloxy)-5-{(1R)-1-hydroxy-2-[({4-methyl-1-[2-(2-phenylethoxy)ethyl]piperidin-4-yl}methyl)amino]ethyl}quinolin-2(1H)-one 
• 948894-29-9 1-{4-methyl-1-[2-(2-phenylethoxy)ethyl]piperidin-4-yl}methanamine 
• 948894-27-7 4-methyl-1-[2-(2-phenylethoxy)ethyl]piperidine-4-carbonitrile 
• 1037792-97-4 4-[4-(4-methanesulfonylphenoxymethyl)thiazol-2-yl]-4-methylpiperidine-1-carboxylic acid tert-butyl ester 
• 951745-01-0 4-methyl-4-thiocarbamoylpiperidine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

Protein Modification at Tyrosine with Iminoxyl Radicals

Post-translational modifications (PTMs) of proteins are a biological mechanism for reversibly controlling protein function. Synthetic protein modifications (SPMs) at specific canonical amino acids can mimic PTMs. However, reversible SPMs at hydrophobic amino acid residues in proteins are especially limited. Here, we report a tyrosine (Tyr)-selective SPM utilizing persistent iminoxyl radicals, which are readily generated from sterically hindered oximes via single-electron oxidation. The reactivity of iminoxyl radicals with Tyr was dependent on the steric and electronic demands of oximes; isopropyl methyl piperidinium oxime 1f formed stable adducts, whereas the reaction of tert-butyl methyl piperidinium oxime 1o was reversible. The difference in reversibility between 1f and 1o, differentiated only by one methyl group, is due to the stability of iminoxyl radicals, which is partly dictated by the bond dissociation energy of oxime O-H groups. The Tyr-selective modifications with 1f and 1o proceeded under physiologically relevant, mild conditions. Specifically, the stable Tyr-modification with 1f introduced functional small molecules, including an azobenzene photoswitch, to proteins. Moreover, masking critical Tyr residues by SPM with 1o, and subsequent deconjugation triggered by the treatment with a thiol, enabled on-demand control of protein functions. We applied this reversible Tyr modification with 1o to alter an enzymatic activity and the binding affinity of a monoclonal antibody with an antigen upon modification/deconjugation. The on-demand ON/OFF switch of protein functions through Tyr-selective and reversible covalent-bond formation will provide unique opportunities in biological research and therapeutics.

N-(PYRIDIN-2-YLSULFONYL)CYCLOPROPANECARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF A CFTR MEDIATED DISEASE

The invention relates to heterocyclic compounds of the formula (I), in which all of the variables are as defined in the specification; capable of modulating the activity of CFTR. The invention further provides a method for manufacturing compounds of the invention, and its therapeutic uses. The invention further provides methods to their preparation, to their medical use, in particular to their use in the treatment and management of diseases or disorders including Cystic fibrosis and related disorders.

2,5-DISUBSTITUTED 3-METHYL PYRAZINES AND 2,5,6-TRISUBSTITUTED 3-METHYL PYRAZINES AS ALLOSTERIC SHP2 INHIBITORS

The present disclosure is directed to inhibitors of SHP2 and their use in the treatment of disease. Also disclosed are pharmaceutical compositions comprising the same.

OXYMETHYLENE ARYL COMPOUNDS FOR TREATING INFLAMMATORY GASTROINTESTINAL DISEASES OR GASTROINTESTINAL CONDITIONS

Use of oxymethylene aryl GPRl 19 agonists, and optionally DPP IV inhibitors and optionally metformin, for the treatment of inflammatory gastrointestinal diseases or gastrointestinal conditions involving malabsorption of nutrients and/or fluids are provide

INDUCTION OF GATA2 BY HDAC1 AND HDAC2 INHIBITORS

Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat diseases or disorders associated with Gata2 deficiency, particularly diseases or disorders that involve any type of HDAC1 and/or HDAC2 expression. Such diseases include acute myeloid leukemia (AML); familial myelodysplastic syndrome (MDS); leukemia; sickle-cell anemia; beta-thalassemia; monocytopenia and mycobacterial infections; dendritic cell, nonocyte, B, and natural killer lymphoid deficiency; Emberger syndrome; asymptomatic neurocognitive impairment; mild neurocognitive disorder; and HIV- associated dementia.

PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS

Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat diseases or disorders associated with HDACl and/or HDAC2 activity.

BROMODOMAIN INHIBITORS AND USES THEREOF

The present invention relates to compounds of formula (I): [INSERT FORMULA (1)] and to salts thereof, wherein R1, R2, Rc, and Rd have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of bromodomains. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various bromodomain-mediated disorders.

PYRIMIDINE HYDROXY AMIDE COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS

Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with HDAC activity, particularly diseases or disorders that involve activity of HDAC1, HDAC2, and/or HDAC6. Also provided herein are methods for inhibiting migration of a neuroblastoma cell, inducing maturation of a neuroblastoma cell, and altering cell cycle progression of a neuroblastoma cell comprising administering to the cell a therapeutically effective amount of a HDAC1, HDAC2, and/or HDAC6 selective inhibitor or a pharmaceutically acceptable salt thereof.

BENZOXAZEPINES AS INHIBITORS OF P13K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE

The invention is directed to Compounds of Formula I: and pharmaceutically acceptable salts or solvates thereof, as well as methods of making and using the compounds. 9936396.1

Pyrrolopyrazine Kinase Inhibitors

The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, wherein the variables n, p, q, Q, X, X′ and Y are defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and inflammatory diseases.